JP2002201141A - 蛋白質合成抑制遺伝子の発現増強剤 - Google Patents
蛋白質合成抑制遺伝子の発現増強剤Info
- Publication number
- JP2002201141A JP2002201141A JP2001116710A JP2001116710A JP2002201141A JP 2002201141 A JP2002201141 A JP 2002201141A JP 2001116710 A JP2001116710 A JP 2001116710A JP 2001116710 A JP2001116710 A JP 2001116710A JP 2002201141 A JP2002201141 A JP 2002201141A
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- gene
- expression
- subtype
- enhancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001116710A JP2002201141A (ja) | 2000-10-27 | 2001-04-16 | 蛋白質合成抑制遺伝子の発現増強剤 |
| CA002395324A CA2395324A1 (en) | 2000-10-27 | 2001-09-26 | Expression potentiator for protein synthesis regulatory gene |
| EP01972507A EP1329223A4 (en) | 2000-10-27 | 2001-09-26 | EXPRESSION AMPLIFIER FOR PROTEIN SYNTHESIS OF REGULATORY GENES |
| KR1020027008401A KR100830268B1 (ko) | 2000-10-27 | 2001-09-26 | 단백질 합성 억제 유전자의 발현 증강제 |
| US09/962,625 US6773701B2 (en) | 2000-10-27 | 2001-09-26 | Expression enhancer for protein synthesis inhibitory genes |
| PCT/JP2001/008390 WO2002036153A1 (en) | 2000-10-27 | 2001-09-26 | Expression potentiator for protein synthesis regulatory gene |
| TW090125438A TWI283582B (en) | 2000-10-27 | 2001-10-15 | Expression potentiator for protein synthesis regulatory gene |
| US10/777,081 US7189389B2 (en) | 2000-10-27 | 2004-02-13 | Pharmaceutical composition of human interferon-α2 and interferon α8 subtypes |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-328539 | 2000-10-27 | ||
| JP2000328539 | 2000-10-27 | ||
| JP2001116710A JP2002201141A (ja) | 2000-10-27 | 2001-04-16 | 蛋白質合成抑制遺伝子の発現増強剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002201141A true JP2002201141A (ja) | 2002-07-16 |
| JP2002201141A5 JP2002201141A5 (cg-RX-API-DMAC7.html) | 2008-05-15 |
Family
ID=26602905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001116710A Pending JP2002201141A (ja) | 2000-10-27 | 2001-04-16 | 蛋白質合成抑制遺伝子の発現増強剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6773701B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1329223A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002201141A (cg-RX-API-DMAC7.html) |
| KR (1) | KR100830268B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2395324A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI283582B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002036153A1 (cg-RX-API-DMAC7.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005089301A (ja) * | 2003-09-12 | 2005-04-07 | Hayashibara Biochem Lab Inc | ウシの消化器疾患治療剤 |
| WO2006095433A1 (ja) | 2005-03-10 | 2006-09-14 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | ウシの消化器疾患治療剤 |
| WO2007037098A1 (ja) | 2005-09-27 | 2007-04-05 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 繁殖障害改善剤 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| CN101031655A (zh) | 2004-07-26 | 2007-09-05 | 陶氏环球技术公司 | 通过株工程改进蛋白表达的方法 |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| US9394571B2 (en) | 2007-04-27 | 2016-07-19 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| CN104056254A (zh) * | 2013-03-18 | 2014-09-24 | 赛德医药科技股份有限公司 | 用以降低肝炎病患复发率的组合物 |
| US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08126494A (ja) * | 1994-11-01 | 1996-05-21 | Kyoto Pasutouule Kenkyusho | インターフェロン活性の測定法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5142199B2 (cg-RX-API-DMAC7.html) | 1972-09-04 | 1976-11-13 | ||
| GB2016015B (en) | 1978-01-22 | 1982-05-06 | Hayashibara Co | Method of preparing interferon and preparations containing interferon |
| JPS5639022A (en) | 1979-09-05 | 1981-04-14 | Hayashibara Biochem Lab Inc | Preparation of vaccine |
| JPS5654158A (en) | 1979-10-09 | 1981-05-14 | Hitachi Ltd | Control system for call waiting |
| JP2838800B2 (ja) | 1989-09-02 | 1998-12-16 | 株式会社林原生物化学研究所 | 減感作剤 |
| US5503828A (en) * | 1992-02-10 | 1996-04-02 | Interferon Sciences, Inc. | Alpha interferon composition and method for its production from human peripheral blood leukocytes |
| JP3232488B2 (ja) | 1992-08-20 | 2001-11-26 | 株式会社林原生物化学研究所 | プルラン高含有物とその製造方法並びに用途 |
| US5780021A (en) * | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
| JPH07163368A (ja) | 1993-12-15 | 1995-06-27 | Hayashibara Biochem Lab Inc | 組換えdnaとその組換えdnaを含む形質転換体 |
| EP0785276A4 (en) | 1994-09-29 | 2002-01-09 | Ajinomoto Kk | MODIFICATION OF A PEPTIDE AND A PROTEIN |
| MY125300A (en) * | 1999-02-26 | 2006-07-31 | Inst Of Molecular And Cell Biology | Synergistic combination for treatment of viral-mediated diseases |
-
2001
- 2001-04-16 JP JP2001116710A patent/JP2002201141A/ja active Pending
- 2001-09-26 US US09/962,625 patent/US6773701B2/en not_active Expired - Fee Related
- 2001-09-26 CA CA002395324A patent/CA2395324A1/en not_active Abandoned
- 2001-09-26 KR KR1020027008401A patent/KR100830268B1/ko not_active Expired - Fee Related
- 2001-09-26 EP EP01972507A patent/EP1329223A4/en not_active Ceased
- 2001-09-26 WO PCT/JP2001/008390 patent/WO2002036153A1/ja not_active Ceased
- 2001-10-15 TW TW090125438A patent/TWI283582B/zh not_active IP Right Cessation
-
2004
- 2004-02-13 US US10/777,081 patent/US7189389B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08126494A (ja) * | 1994-11-01 | 1996-05-21 | Kyoto Pasutouule Kenkyusho | インターフェロン活性の測定法 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005089301A (ja) * | 2003-09-12 | 2005-04-07 | Hayashibara Biochem Lab Inc | ウシの消化器疾患治療剤 |
| WO2006095433A1 (ja) | 2005-03-10 | 2006-09-14 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | ウシの消化器疾患治療剤 |
| WO2007037098A1 (ja) | 2005-09-27 | 2007-04-05 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 繁殖障害改善剤 |
| JPWO2007037098A1 (ja) * | 2005-09-27 | 2009-04-02 | 株式会社林原生物化学研究所 | 繁殖障害改善剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1329223A1 (en) | 2003-07-23 |
| KR100830268B1 (ko) | 2008-05-16 |
| US6773701B2 (en) | 2004-08-10 |
| US20040197307A1 (en) | 2004-10-07 |
| US7189389B2 (en) | 2007-03-13 |
| CA2395324A1 (en) | 2002-05-10 |
| KR20020065620A (ko) | 2002-08-13 |
| EP1329223A4 (en) | 2005-04-20 |
| US20030039629A1 (en) | 2003-02-27 |
| TWI283582B (en) | 2007-07-11 |
| WO2002036153A1 (en) | 2002-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Matikainen et al. | Influenza A and sendai viruses induce differential chemokine gene expression and transcription factor activation in human macrophages | |
| KR100223255B1 (ko) | 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법 | |
| Wang et al. | Extracellular role of HMGB1 in inflammation and sepsis | |
| KR100537558B1 (ko) | 인터류킨-18 결합 단백질 | |
| HUT77747A (hu) | A BDNF és az NT-3 konjugátumai vízoldható polimerrel képezett konjugátumai | |
| WO1990000397A1 (en) | A pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers | |
| EA014157B1 (ru) | РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2) | |
| KR102249454B1 (ko) | 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드 | |
| Masci et al. | New and modified interferon alfas: preclinical and clinical data | |
| CN103483443A (zh) | 重组人干扰素样蛋白 | |
| US6773701B2 (en) | Expression enhancer for protein synthesis inhibitory genes | |
| EP1326628B1 (en) | Chemokine mutants in the treatment of multiple sclerosis | |
| JP3226918B2 (ja) | 腫瘍壊死因子とインターロイキン−4の相乗作用 | |
| JPH0550273B2 (cg-RX-API-DMAC7.html) | ||
| Zheng et al. | Yak IFNβ-3 enhances macrophage activity and attenuates Klebsiella pneumoniae infection | |
| Lipiński et al. | Protective effect of tissue ferritins in experimental Escherichia coli infection of mice in vivo | |
| KR100530125B1 (ko) | 개의난치성피부염의치료제및치료방법 | |
| US6774220B1 (en) | Compounds having lectinic properties and their biological applications | |
| RU2003334C1 (ru) | Способ лечени больных с опухол ми | |
| US20250082734A1 (en) | Ptprs in autoimmunity | |
| KR20200066628A (ko) | 돼지 g-csf 변이체 및 그 용도 | |
| JPH1057080A (ja) | L−アスパラギナーゼ活性を有する哺乳類由来のポリペプチド | |
| JP4866612B2 (ja) | 生理活性複合体 | |
| JPH09157180A (ja) | 感受性疾患剤 | |
| JPS63190830A (ja) | 抗悪性腫瘍剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080402 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080402 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110315 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110510 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120110 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120529 |